Healthcare >> Analyst Interviews >> December 11, 2014
Strong Fundamentals in Biotech Justify Even Higher Valuation Levels
Dr. Jason Kantor is a Managing Director of Credit Suisse Group and a Senior Analyst covering the U.S. biotechnology sector, with a focus on small and midcap stocks. He joined Credit Suisse Group in 2012. Prior to joining the bank, Dr. Kantor held positions of Managing Director and Senior Biotechnology Analyst at RBC Capital Markets, 2005 to 2012; Managing Director and Senior Biotechnology Analyst at WR Hambrecht + Co, 2002 to 2005; and Vice President in equity research at J.P. Morgan Chase & Co from 1998 to 2002. Dr. Kantor’s health care expertise covers several important categories including oncology, cardiology, antibody technology and infectious disease. He has had several independent recognitions including: Fortune All-Star Analyst in 2004, The Wall Street Journal ranked him number two in 2004 and number four in 2010 in its Best on the Street survey, and the Financial Times and StarMine ranked him number two for earnings estimations in 2010. Dr. Kantor received his B.A. cum laude in biology from the University of California, San Diego, and his Ph.D. in cell and developmental biology from Harvard University. Profile
TWST: Can you tell us about your area of expertise?
Dr. Kantor: I have been doing sellside biotech research since 1997. I am a Ph.D. Cell Biologist by training, and I focus primarily on